


Supplemental Materials

SARS-CoV-2 Vaccination and Immune Thrombocytopenia in de novo and pre-existing ITP patients

Eun-Ju Lee,¹ Marina Beltrami-Moreira,¹ Hanny Al-Samkari,² Adam Cuker,³ Jennifer DiRaimo,⁴ Terry Gernsheimer,⁵ Alexandra Kruse,⁴ Craig Kessler,⁶ Caroline Kruse,⁴ Andrew D. Leavitt,⁷ Alfred I. Lee,⁸ Howard A. Liebman,⁹ Adrian C. Newland,¹⁰ Ashley E. Ray,¹ Michael D. Tarantino,¹¹ Jecko Thachil,¹² David J. Kuter,² Douglas B. Cines,³ and James B. Bussel.¹³

Figure S1. Treatments and platelet responses in 15 ITP patients who received rescue treatment following SARS-CoV-2 vaccination. Horizontal dotted line marks platelet count of $30 \times 10^9/L$. Y axis is log base 2 scale. X axis is days related to either first or second dose of vaccine administration.




IVIG: intravenous immunoglobulin; TPO RA: TPO receptor agonist

*Time from baseline platelet count to beginning of immunization series varied, the graph represents all baseline platelet count at day 0 of immunization series.

“Second dose” is presumed as day 21 and day 28 for Pfizer-BioNTech and Moderna vaccines, respectively.

¶ received rescue therapy after the first and second vaccine doses.

Figure S2. Pre- and post-vaccination platelet counts following each dose of an mRNA SARS-CoV-2 vaccination stratified by relative change in platelet count from baseline following dose #1.



Dotted horizontal line indicates platelet count 30 x10⁹/L

Table S1. Platelet Disorder Support Association survey results from patients with ITP and reported platelet counts following SARS-CoV-2 vaccination

Characteristic Mean \pm SD, Median [IQR], or n (%)	Platelet count stable or increase (n=38)	N	Platelet count decreased (n=19)	N	Relative Risk (RR)
Age	50 \pm 15.6	37	53.6 \pm 18.1	19	
Gender		38		19	
Male	9 (23.7%)		4 (20%)		
Female	29 (76.3%)		14 (70%)		
History of autoimmune disorders		38		19	
ITP only	34 (89.5%)		16 (76.2%)		
Other autoimmune condition	Evans Syndrome: 1 Thyroid disease: 1 Undifferentiated connective tissue disease: 1 Unknown: 1		Evans Syndrome: 1 Systemic Lupus Erythematosus: 2		
ITP status¶		38		19	
Remission	17 (44.7%)		1 (4.7%)		0.7 [0.4—0.9]
Active	14 (36.8%)		15 (71.4%)		
Not sure	7 (18.4%)		3 (14.3%)		
ITP therapy within the previous 6 months¶		34		19	
TPO-RA only	2 (5.9%)		4 (21%)		
Steroid only	2 (5.9%)		5 (26.3%)		
“Antibiotics” only	2 (5.9%)		0		
More than 1 therapy*	5 (14.7%)		5 (26.3%)		NS
No therapy	23 (67.6%)		5 (26.3%)		0.6 [0.4—0.91]
History of splenectomy	7 (18.4%)	38	9 (42.8%)	19	1.8 [1.1—3.4]
Vaccine manufacturer		38		19	
Moderna	19 (50%)		10 (52.4%)		
Pfizer-Bio-NTech	15 (39.5%)		8 (42.8%)		

Oxford-AstraZeneca	3 (7.9%)		1 (4.8%)		
Janssen	1 (2.6%)		0		
Prior history of decrease in platelet count after other immunizations		38		19	
Yes	3 (7.9%)		3 (15.8%)		
No	15 (39.5%)		6 (31.6%)		
Not sure	20 (52.6%)		10 (52.6%)		

SD: standard deviation, IQR: interquartile range, NS: not significant, TPO-RA: thrombopoietin receptor agonist

¶ excludes 2 patients with post-vaccine thrombocytopenia; odds ratio and P value for active ITP vs remission.

*Includes corticosteroid + IVIG, corticosteroid + rituximab, corticosteroid + rituximab + IVIG + antibiotic, corticosteroid + fostamatinib, TPO-RA + IVIG, and combination TPO-RA